Treatment of visceral leismaniasis in HIV patients with a new regimen of liposomal amphotericin;Tratamiento de la coinfección VIH-leishmaniasis visceral con un nuevo régimen de anfotericina B liposomal (AMB-L)

Medicina Clinica

Volumn 116, Issue 10, 2001, Pages 395-

  Canora Lebrato, Jesús ^a   Troncoso García, Esther ^a   Escobar, Trinidad ^a   Hernández Quero, José ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

COMORBIDITY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; NONHUMAN; VISCERAL LEISHMANIASIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIASIS, VISCERAL; LIPOSOMES;

EID: 0035901206     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(01)71839-8     Document Type: Article

References (4)

1. A. Meyerhoff U.S. Food and Drug Administration approval of Ambisome (liposomal amphotericin B) for treatment of visceral lesihmaniasis Clin Infect Dis 28 1999 42 48
2. P. Rodríguez-Wilhelmi C. Panizo E. Ruza E. Rocha Tratamiento con anfotericina B liposomal en tres pacientes inmunodeprimidos con leishmaniasis visceral Med Clin (Barc) 116 2001 37 38
3. E.W.M. Van Etten M.T. Kate S.V. Snijders J.M.B. Bakker-Woudenberg Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system Antimicrob Agents Chemother 42 1998 1677 1681
4. T.J. Walsh V. Yeldandi M. McEvoy C. González S. Chanock A. Freifeld Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (Ambisome) in neutropenic patients Antimicrob Agents Chemother 42 1998 2391 2398